Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [1] Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies.
    Phan, Alexandria T.
    Wolin, Edward M.
    Fisher, George A.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Liyanage, Nilani
    Strutt, Kristina
    Braun, Stephan
    Caplin, Martyn E.
    Vinik, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Safety and Tolerability of Lanreotide Autogel/Depot in Patients With Neuroendocrine Tumors: Pooled Analysis of Clinical Studies
    Phan, Alexandria T.
    Wolin, Edward M.
    Fisher, George A., Jr.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Liyanage, Nilani
    Mirakhur, Beloo
    Braun, Stephan
    Caplin, Martyn E.
    Vinik, Aaron I.
    PANCREAS, 2018, 47 (03) : 351 - 351
  • [3] Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
    Buil-Bruna, N.
    Jesus Garrido, M.
    Dehez, M. B.
    Manon, A.
    Nguyen, T. X. Q.
    Gomez-Panzani, E.
    Troconiz, I. F.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 122 - 122
  • [4] Exploratory analysis of tumor growth rate (TGR) with lanreotide depot/autogel (LAN) in patients (pts) with neuroendocrine tumors (NETs) from the CLARINET study
    Caplin, Martyn E.
    Pavel, Marianne E.
    Ruszniewski, Philippe
    Liyanage, Nilani
    Massien, Christine
    Dromain, Clarisse
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)
    Caplin, M.
    Pavel, M.
    Cwikla, J. C.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wolin, E.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Liyanage, N.
    Braun, S.
    Ruszniewski, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
    Buil-Bruna, Nuria
    Jesus Garrido, Maria
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Gomez-Panzani, Edda L.
    Troconiz, Inaki F.
    CLINICAL PHARMACOKINETICS, 2016, 55 (04) : 461 - 473
  • [9] Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study
    Pavel, M.
    Dromain, C.
    Massien, C.
    Houchard, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
    Núria Buil-Bruna
    María Jesús Garrido
    Marion Dehez
    Amandine Manon
    Thi Xuan Quyen Nguyen
    Edda L. Gomez-Panzani
    Iñaki F. Trocóniz
    Clinical Pharmacokinetics, 2016, 55 : 461 - 473
12345